AU2018288712A1 - Methods for treating merkel cell carcinoma (MCC) using NK-92 cells - Google Patents

Methods for treating merkel cell carcinoma (MCC) using NK-92 cells Download PDF

Info

Publication number
AU2018288712A1
AU2018288712A1 AU2018288712A AU2018288712A AU2018288712A1 AU 2018288712 A1 AU2018288712 A1 AU 2018288712A1 AU 2018288712 A AU2018288712 A AU 2018288712A AU 2018288712 A AU2018288712 A AU 2018288712A AU 2018288712 A1 AU2018288712 A1 AU 2018288712A1
Authority
AU
Australia
Prior art keywords
cell carcinoma
merkel cell
methods
cells
mcc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018288712A
Other languages
English (en)
Inventor
Laurent BOISSEL
Hans Klingemann
Tien Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunitybio Inc
Original Assignee
Immunitybio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunitybio Inc filed Critical Immunitybio Inc
Publication of AU2018288712A1 publication Critical patent/AU2018288712A1/en
Assigned to IMMUNITYBIO, INC. reassignment IMMUNITYBIO, INC. Amend patent request/document other than specification (104) Assignors: NANTKWEST, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018288712A 2017-06-20 2018-06-19 Methods for treating merkel cell carcinoma (MCC) using NK-92 cells Abandoned AU2018288712A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522335P 2017-06-20 2017-06-20
US62/522,335 2017-06-20
PCT/US2018/038308 WO2018236887A1 (en) 2017-06-20 2018-06-19 Methods for treating merkel cell carcinoma (mcc) using nk-92 cells

Publications (1)

Publication Number Publication Date
AU2018288712A1 true AU2018288712A1 (en) 2019-12-12

Family

ID=62875317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018288712A Abandoned AU2018288712A1 (en) 2017-06-20 2018-06-19 Methods for treating merkel cell carcinoma (MCC) using NK-92 cells

Country Status (9)

Country Link
US (1) US20200171087A1 (enExample)
EP (1) EP3641790A1 (enExample)
JP (1) JP2020524164A (enExample)
KR (1) KR20200017494A (enExample)
CN (1) CN110753551A (enExample)
AU (1) AU2018288712A1 (enExample)
CA (1) CA3066463A1 (enExample)
IL (1) IL270838A (enExample)
WO (1) WO2018236887A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102476640B1 (ko) 2013-11-01 2022-12-09 이뮤너티바이오, 인크. 종양세포 치사활성 및 항균성 조성물 및 방법
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7267398A (en) 1997-04-30 1998-11-24 Hans Klingemann Natural killer cell lines and methods of use

Also Published As

Publication number Publication date
EP3641790A1 (en) 2020-04-29
KR20200017494A (ko) 2020-02-18
CA3066463A1 (en) 2018-12-27
IL270838A (en) 2020-01-30
JP2020524164A (ja) 2020-08-13
US20200171087A1 (en) 2020-06-04
WO2018236887A1 (en) 2018-12-27
CN110753551A (zh) 2020-02-04

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
WO2019220369A3 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
MX2020005463A (es) Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
EP4599848A3 (en) Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
MX2021005398A (es) Terapia del cancer con celulas inmunitarias anti-cd33.
MX385562B (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2.
MY194058A (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
EP4268892A3 (en) Matrix bound nanovesicles and their use
MX2022005411A (es) COMPUESTOS DE UNIÓN A IL-2RßYC.
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
MX2015012922A (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular.
MX2019010039A (es) Composiciones y métodos para transducción de tumores.
MX2018005348A (es) Composiciones y metodos para transduccion de tumores.
MX2019010382A (es) Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
PH12015501002A1 (en) Treatment of cancer with pomalidomide in a renally impaired subject
MX2019013862A (es) Terapia de combinacion.
MX2020001727A (es) Terapia de combinacion.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
SG11201806177QA (en) Transplant material for treatment of heart disease
MY158929A (en) Pharmaceutical combination
WO2020072519A8 (en) Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
HK1257882A1 (zh) 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法
BR112018011196A2 (pt) uso de pirimido-pirimidazinonas para tratar o câncer

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: IMMUNITYBIO, INC.

Free format text: FORMER NAME(S): NANTKWEST, INC.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application